Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors Apr 19, 2021
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors Mar 25, 2021
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference Feb 22, 2021
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy Feb 12, 2021
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™ Feb 2, 2021
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Jan 25, 2021
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™ Dec 21, 2020
